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Purpose: To compare frequently used classification systems for age-related macular
degeneration (AMD) in their abilty to predict late AMD.
Methods: In total, 9066 participants from the population-based Rotterdam Study were
followed up for progression of AMD during a study period up to 30 years. AMD lesions
were gradedon color fundus photographs after confirmation onother imagemodalities
andgrouped at baseline according to six classification systems. LateAMDwasdefined as
geographic atrophy or choroidal neovascularization. Incidence rate (IR) and cumulative
incidence (CuI) of late AMDwere calculated, and Kaplan-Meier plots and area under the
operating characteristics curves (AUCs) were constructed.
Results: A total of 186 persons developed incident late AMD during a mean follow-up
time of 8.7 years. The AREDS simplified scale showed the highest IR for late AMD at 104
cases/1000 py for ages <75 years. The Rotterdam classification showed the highest IR
at 89 cases/1000 py >75 years. The 3-Continent harmonization classification provided
the most stable progression. Drusen area >10% ETDRS grid (hazard ratio 30.05, 95%
confidence interval [CI] 19.25–46.91) was most prognostic of progression. The highest
AUC of late AMD (0.8372, 95% CI: 0.8070-0.8673) was achieved when all AMD features
present at baseline were included.
Conclusions: Highest turnover rates from intermediate to late AMD were provided by
the AREDS simplified scale and the Rotterdam classification. The 3-Continent harmo-
nization classification showed the most stable progression. All features, especially
drusen area, contribute to late AMD prediction.
Translational Relevance: Findings will help stakeholders select appropriate classifica-
tion systems for screening, deep learning algorithms, or trials.
Introduction
Late age-related macular degeneration (AMD)
causes blindness in approximately 11 million people
worldwide. This number is expected to increase to
19 million by 2040.1,2 With growing numbers and
substantial social and economic burden, the disease
remains a major public health problem. Several devel-
opments aimed at improvement of clinical manage-
ment of AMDare ongoing.New drugs are under inves-
tigation, of which many have reached phase 3: 136
clinical trials investigating new interventions for AMD
are currently registered (clinicaltrial.gov).3 Another
important development particularly for screening is the
automated grading of retinal images using deep learn-
ing algorithms.4–6 Both developments require accurate
classification systems: trials need clear criteria for
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inclusion with relatively high rates of outcome events,
whereas automated algorithms need validation by a
“ground truth.”
During the past three decades, several classifica-
tion systems have been developed for clinical and
epidemiologic purposes. Most characterize geographic
atrophy (GA) and subretinal choroidal neovascu-
larization (CNV) as the end stages.7,8 Drusen and
pigmentary abnormalities are generally considered
early stages, but severity classes of these features differ
markedly between studies.9 Until now, it remained
unclear how well the classification systems perform in
terms of prognosis and progression to end stage AMD,
and it is undetermined which system works best for
what purpose.
In the prospective population-based Rotterdam
Study, we compared frequently used AMD classifica-
tion systems and their ability to predict the occurrence
of late AMD. We subsequently evaluated the use of
the systems for various applications, such as screening
and clinical trials. We quantified all AMD features at
baseline, categorized patients according to frequently
used classification systems, and calculated incidence
of late AMD per stratum in middle-aged and elderly
subjects.
Methods
Ethics Statement
The Rotterdam Study was approved by the medical
ethics committee of the Population Study Act, and was
conducted according to the tenets of theDeclaration of
Helsinki. Written informed consent was obtained from
each participant.
Study Design and Subjects
The study population was derived from the
prospective, population-based cohort the Rotter-
dam study (RS), which has been described in detail
elsewhere.10 This study was set up to assess determi-
nants of age-related diseases in the general population,
and consisted of three subsequent cohorts within
Ommoord, a well-defined district in the city of Rotter-
dam, the Netherlands. The initial cohort, RS-1, which
started in 1989, consisted of 7983 participants, aged
55 years and older. The second cohort, RS-2, started
in 2000 and consisted of 3011 new participants, aged
55 years and older. A final cohort, RS-3, was added
in 2006, which consisted of 3932 participants, aged 45
years and older. A total of 14,926 participants were
included in the RS, of which 11,571 (78%) partici-
pants had eye examinations and a baseline age of 55
years and older. Reexaminations took place every 3 to
4 years, with a total of five visits available for RS-1,
three visits available for RS-2, and two visits for RS-3.
For the current analyses, we excluded 29 participants
with nongradable fundus photographs at baseline, and
141 participants with prevalent late AMD. Further
exclusion of participants with less than 1 follow-up
visit resulted in a final cohort of 9066 persons at risk
for incident late AMD (Supplemental Figure S1).
Ascertainment, Grading, and Classification
At the eye examinations, color fundus photographs
were taken with Topcon TRV-50VT (Topcon Optical
Company, Tokyo, Japan) for the first three visits and
withTopcon TRC 50EX and the Sony DXC-950P
digital camera (0.44megapixel) for the remaining visits.
OCT images were taken with SD-OCT (Topcon Corp.,
Tokyo, Japan) since 2007. Fundus autofluorescence
and near infrared images were taken with Heidelberg
Retina Angiograph 2 (Heidelberg Engineering, Heidel-
berg, Germany). Two experienced graders from the
Eye-NED Reading Center graded AMD lesions on
color fundus photographs after visual confirmation
of the lesions on the other image modalities. Crite-
ria for lesions were according to a modified version
of the Wisconsin Age-related Maculopathy Grading
System.11 AMD gradings at baseline were categorized
per eye according to six classification systems (Table 2).
Individuals received the grade of the worse eye. The
AREDS simplified scale gives individuals a point for
presence of large drusen or pigment changes in each
eye, with amaximum score of 4 for both lesions present
in each eye.12 The scale was analyzed as such, but also in
a modified version for worse eye analysis to correspond
with the other studies. Then, the maximum score was 2
for presence of both lesions.
GA was considered present when a sharply delin-
eated round or oval area of RPE atrophy (≥0.024mm2)
with apparant choroidal vessels was visible on color
fundus photo, and when an additional region of hyper-
transmission and disappearance of RPE was visible
on OCT.13,14 Choroidal neovascularization (CNV) was
considered present when a subretinal or sub-RPE
neovascular membrane was visible, or retinal scarring,
subretinal hemorrhage, serous RPE detachment in
combination with drusen and/or hard exudates were
visible on color fundus photo and OCT.13
Statistical Analysis
All statistical analyses were carried out using R,
version 3.5.3 (RCore Team, 2016), and SPSS Statistics,
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Table 1. Baseline characteristics of subjects at risk of incident late AMD
Subjects in Analysis* (n= 9066)
Characteristics Non-cases (n= 8880) Incident Cases† (n= 186) P
Age, years, mean (SD) 65.4 (7.7) 70.3 (7.7) <0.0001
Age, years (%)
55-65 58.0 26.9 <0.0001
65-75 28.4 45.1
75-85 11.9 24.2
85+ 1.7 3.8
Gender (% male)§ 42.4 41.4 0.740
Ethnicity (%)§ n= 7,897 n= 173
Caucasian 98.3 99.4 0.303
Body mass index, mean
(SD)§
26.8 26.4 0.235
Hypertension (%)§ n= 8,791 n= 184
Present 59.1 59.2 0.054
Smoking (%)§ n= 8,802 n= 181
Present 22.1 24.1 0.033
Features at baseline (%)§
Drusen≥63 μm 58.5 43.0 <0.0001
Drusen≥125 μm 7.7 48.9
Drusen area in grid>10% 0.9 22.0
Hyperpigmentation 7.4 31.8
RPE degeneration 7.8 28.5
*Subjects >55 years of age, with eye examinations, gradable fundus photos, no prevalent late AMD, and at least one
follow-up visit.
†Subjects with incident late AMD.
§Sdjusted for age and sex.
version 24.0.0.1 (IBM, Armonk, NY). Differences in
baseline characteristics adjusted for age and sex were
evaluated using logistic regression analysis. Incidence
analyses were performed for two age strata: younger
than 75 years and 75+ years at baseline. Incidence
rates (IR) of late AMD were calculated as the
number of incident cases per 1000 person years (py).
The event of incident late AMD was assumed to
have occurred halfway during the interval between
two subsequent visits; this was the same for lost-
to-follow-up. IR of late AMD were calculated per
category of each classification system, as well as
per lesion at baseline (i.e., drusen type, drusen area,
hyperpigmentation, and RPE-degeneration). Cumula-
tive incidences (CuI) of late AMD were calcu-
lated from the incidence rates with the formula
CI = 1 - e(-IR x T).
To evaluate performance, receiver operating curves
with area under the curve (AUC) and positive predic-
tive values (PPV) of late AMD were computed per
category of each classification system. AUCs could
range from 0.5 (no prediction) to 1 (perfect predic-
tion). The sum of AUCs from all categories within a
classification system represented the overall discrimi-
native ability for the occurrence of late AMD for that
system.
Univariate Cox proportional hazards models were
used to evaluate the association between baseline
drusen type, drusen area, hyperpigmentation, RPE-
degeneration, and incident late AMD. Hazard ratios
were graphically represented by plotting log-minuslog
survival function over time for age groups <75 and
75+ years. Varying logistic regression models of late
AMD were used to construct AUCs. Model 1 was
the simplest model, which contained age and sex as
variables. Model 2 included age, sex, and presence of a
drusen area of >10% within the ETDRS grid. Model
3 included age, sex, and presence of pigment changes.
Model 4 included age, sex, and presence of drusen ≥
125 μm. Model 5 included all features. We used the
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Table 2. Baseline AMD features per classification system
Drusen Pigment Changes Late Changes
Year
Classification
System Type Size Area
Hyper-
pigmentation
RPE
Degeneration GA GA sub* CNV Mixed
2001 Rotterdam16
√ √
x
√ √ √
x
√ √
2001 AREDS17 x
√ √ √ √ √ √ √ √
2005 AREDS 9-step18 x x
√ √ √
x
√
x x
2005 AREDS simplified12 x
√
x
√ √
x x x x
2013 Beckman19 x
√
x
√ √ √
x
√ √
2014 3-Continent
harmonization20
x
√ √ √ √ √
x
√ √
*GA subspecified: classification system subspecified GA into central and noncentral GA.
Abbreviations: CNV, choroidal neovascularization; GA, geographic atrophy; mixed, mixed phenotype of both GA
and CNV.
bootstrap method to find bootstrap optimism-
corrected AUCs.
Results
Characteristics of the study population are shown
in Table 1. Subjects who developed incident late
AMD significantly differed from other eligibles by
age, smoking status, and baseline AMD features after
adjustment for age and sex. Differences for baseline
characteristics between subjects in-analysis and not-in-
analysis are shown in Supplemental Table S1.
The specific AMD features included in the classifi-
cation systems are shown in Table 2. Total drusen area
as a feature was not included in the Rotterdam classifi-
cation, the AREDS simplified scale, or the Beckman
classification. Classification of drusen type was only
included in the Rotterdam classification. Noncentral
GA as a feature for late changes was only used in
the AREDS classification and the AREDS 9-step
scale.
Overall Incidence Rate of Late AMD
During a mean follow-up of 8.7 (standard devia-
tion [SD] 5.0) years, 186 persons developed incident
late AMD; 73 (39%) were diagnosed as GA, 83 (45%)
as CNV, and 30 (16%) as mixed late AMD. Mean
age of onset of late AMD was 77.9 (SD 7.3). RS-1
provided 145 cases (78%) of incident late AMD during
mean follow-up of 9.6 (SD 5.9) years. RS-2 and RS-
3 provided 28 (15%) and 13 (7%) cases during a mean
follow-up of 8.6 (SD 3.0) and 5.6 (SD 0.5), respectively
(Supplemental Table S2).
Given a total of 89548 py in RS1-3 and age
45+ years, the overall incidence rate of late AMD
was 2.1/1000py. The 2-, 5-, and 10-year cumulative
incidences were 0.4%, 1.0%, and 2.1%, respectively.
Incidence Rates of Late AMD Per
Classification System
In the younger age group, incidence rates ranged
from 0.4/1000 py in the lowest category to 104
cases/1000 py in the highest category. In the older age
group, incidence rates similarly increased from0.4/1000
py to 89/1000 py for the age group 75+ years. Rates
increased with higher severity levels in all classifica-
tions (Fig. 1). The AREDS simplified scale showed
the highest incidence rate, category 4 had a rate of
104 cases/1000 py for participants aged<75 years. The
Rotterdam classification showed the highest incidence
rate at category 3 with 89 cases/1000 py for participants
aged 75+ years. The 3-Continent harmonization classi-
fication showed the most stable progression between
categories for both age groups. Because the AREDS
simplified scale uses fellow eyes, we also examined
incidence rates of a modified version for single eyes
(Supplemental Figure S2).
Cumulative Incidences of Late AMD Per
Classification System
Cumulative incidences of late AMD per system are
shown in Figure 2. The risk of late AMD ranged from
0.1% in the lowest category to 65% in the highest for
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Figure 1. Incidence rates plotted per category in various AMD classification systems. Numbers of incident cases and person years per
subclass are shown below the incidence rate plots, with numbers for ages>75 years post-slash.
Figure 2. Cumulative incidences of late AMD per subclass and classification system at 2, 3, 5, and 10 years. Different colors represent
different subclasses within a system. Subjects aged<75 years old are depicted with a dotted line.
the age group <75 years, and from 0.1% to 58% for
the age group 75+ years. Rates generally increased
with higher severity levels. Cumulative incidences of a
modified worse-eye AREDS simplified scale are shown
in Supplemental Figure S2.
Overall Performance Per Classification
System
Systems showed similar overall ability in discrim-
inating late AMD, with AUCs ranging from 0.759
Downloaded from tvst.arvojournals.org on 09/23/2020
Performance of Classification Systems for AMD TVST | Special Issue | Vol. 9 | No. 2 | Article 26 | 6
Figure 3. Incidence rates of late AMD per feature. Incident cases and person years are shown below the plots, ages>75 post-slash.
to 0.817 (Supplemental Figure S3). The Rotterdam
classification showed the highest AUC of 0.817 (95%
CI: 0.781-0.852) PPV per system increased with
higher category, in correspondance with results from
incidence analyses (Supplemental Figure S4). The
AREDS simplified scale scored the highest PPV with
in the highest category 19 of 38 individuals (50%) who
developed late AMD over time.
Incidence Rates and Cumulative Incidences
Per Baseline AMD Feature
Incidence of late AMD per feature determined at
baseline increased with age and with severity or size
of features (Fig. 3). The highest incidence rate of late
AMD, for both age groups, was found in participants
with drusen areas of >10% within the ETDRS grid
at baseline (incidence rate: 51.6 - 54.9 cases/1000 py).
Cumulative incidences at 2, 3, 5, and 10 years are shown
in Figure 4.
Survival Analysis
Drusen type, drusen area ≥10% in ETDRS grid,
hyperpigmentation, and RPE degeneration all showed
a significantly increased hazard for lateAMD, indepen-
dent of age group. Presence of drusen area ≥10% in
ETDRS grid showed the highest cumulative hazard
(hazard ratio [HR] 30.05, 95% confidence interval [CI])
19.25–46.91; P < 2e-16). HRs for all baseline features
are shown in Supplemental Table S3. Correspond-
ing cumulative hazard plots for ages <75 are shown
in Figure 5, for ages group >75 in Figure 6.
Discriminative Ability
Discriminative ability for incident late AMD
increased from AUC 0.6866 (95% CI: 0.6500 – 0.7232)
for the simplest model (model 1), which included only
age and sex, to AUC 0.8372 (95% CI: 0.8070-0.8673)
for model 5, which included age, sex, drusen area≥10%
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Figure 4. Cumulative incidence of late AMD per feature determined at baseline. Subjects aged<75 years old are depicted with a dotted
line.
in the ETDRS grid, pigment changes, and drusen
≥ 125μm (Fig. 7). Other models that included age,
sex, and either drusen area/pigment changes/large
drusen showed comparable, but lower discriminative
ability. AUCs and corresponding CIs are shown in
Supplemental Table S4.
Discussion
We compared the prediction of late AMDby several
frequently used classification systems in the large,
longrunning, prospective population-based Rotterdam
Study. Here, 186 of 9066 (2.1%) individuals aged 55+
years developed late AMD with a mean age of onset
of 77.9 years. Risk of late AMD increased with higher
categories and age in most systems. The AREDS
simplified classification and the Rotterdam classifica-
tion both had high-risk categories that predicted a
high turnover from intermediate to late AMD, whereas
the 3-Continent harmonization classification showed
the most stable progression across all its categories.
We confirmed that features such as drusen area and
pigment changes increase disease progression, and
show that prediction of late AMD is improved by
combining all early and intermediate AMD features.
Various classification systems for AMD lesions have
been published during the past 30 years. In the early
1990s, the Wisconsin age-related maculopathy grading
system set the tone for the diagnostic criteria of individ-
ual AMD lesions in a macular grid with subfields
and standard circles to assess size and area. This
was followed by an international consensus on AMD
lesions by the International Age-Related Maculopathy
Epidemiological Study Group.13,15 As these systems
lacked a severity scale, a classification system address-
ing this was established by the Rotterdam Study Group
in 2001.16 The AREDS Study proposedmultiple classi-
cation systems, of which the first system was published
in 2001, classifying referable patients for AREDS
supplements. Several years later, two systems were
added by this study group for clinical and research
purposes (i.e., a simplified scale and a 9-step sever-
ity scale, respectively).12,17,18 More recently, a clinical
classification was published by the Beckman initiative
group in 2013, and an AMD severity scale quantifying
lesions by the 3CC study in 2014, which harmonized
grading of the Rotterdam Study, the Beaver Dam Eye
Study, the Los Angeles Latino Eye study, and the Blue
Mountain Eye Study.19,20
Our results point out the potential advantages
and disadvantages of these classification systems.
Although all systems are based on color fundus
photographs, they vary in their stratification of graded
features. As purposes for classifiying disease may differ
between potential stakeholders (i.e., ophthalmologists,
optometrists, researchers, and engineers), we evaluated
classification systems according to possible goals of
screening, automated grading, and clinical trials (i.e.,
ability to find high event rates as well as stable progres-
sion rates of late AMD; Supplemental Table S5).
For screening and referals, systems should be quick
and easy to interpret. The AREDS simplified scale
seems appropriate in this regard with limited and
easily identifiable features (i.e., presence of large drusen
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Figure 5. Cumulative hazard plots per AMD baseline feature for ages<75 years, with number at risk per group shown below plots.
and pigment changes). The Beckman classification is
similar, but also classifies drusen according to size in
small, intermediate, and large drusen, which may still
be feasible for screening. This system, however, did not
reveal high progression rates in any of the categories.
For intervention studies focusing on early and inter-
mediate AMD, systems should include categories with
a high turnover rate to late AMD. Both the AREDS
simplified scale and the Rotterdam Study had such
categories.
More elaborate analyses of risk prediction require
detailed phenotyping and systems that are able to
find a stable progression rate between categories.
The AREDS 9-step scale has great detail in grading
of drusen areas and RPE-degeneration, allowing for
many categories. Category 7, however, produced an
event rate that was substantially higher than subse-
quent levels. This contrasts earlier findings, which
showed stable progression and a rising incidence of
late AMD.18 The 3-Continent harmonization, which
quantifies drusen area, was the only system in which
progression was consistent with a continuous increas-
ing risk of late AMD.
Artificial intelligence systems for classification of
AMD generally need a well-defined “ground truth” or
reference standard to demonstrate their performance.
Algorithms can be made using any of the classifica-
tion systems, and the choice depends on the needs of
the user. Nevertheless, we show here that all features
of early and intermediate AMD, type of drusen,
drusen area, and presence of pigmentary changes
contribute to late AMD prediction. Algorithms that
detect and quantify all individual lesions are more
likely to be useful for a wide variety of purposes,
and be more precise in risk-analyses of future events.
Currently available automated grading systems mostly
focus on classification of disease or on a referral
stage, making these systems inflexible. Hence, more
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Figure 6. Cumulative hazard plots per AMD baseline feature for ages>75 years, with number at risk per group shown below plots.
in-depth development of lesion level algorithms is
needed.
This study has strengths and limitations. Our study
period was lengthy, but as AMD develops in older
persons, the mean total follow-up time was less than
a decade because of mortality. Another point of
discussion is that while we graded individual lesions
after viewing all image modalities, the classification
systems were based on color fundus photographs
only; multimodal classification systems have not been
published yet. Except for age, effects of other known
demographic, environmental, and genetic risk factors
were not included in the analyses as this was outside
the scope of this study. However, incorporation of
these factors would increase prediction of late AMD.
To date, only one earlier study addressed perfor-
mance of classification systems, and also showed higher
prevalences of early and intermediate AMD in the
3-harmonization classification as compared to the
Beckman clinical classification.21 This study under-
lined the need to clarify the use and purpose of the
different systems.
In summary, we compared incidence of late AMD
in various classification systems and propagate that
each has its advantages and disadvantages. Our results
will help researchers and clinicians select appropriate
classification systems for applications such as screen-
ing or intervention studies.
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